Kidney Cancer Serum
Powered by BiozAbout:Kidney Cancer Serum from consented donors with confirmed kidney cancer, processed and frozen within 24 hours of collection. Supports angiogenesis and VEGF pathway biomarker work reflecting VHL/HIF biology in clear cell renal cell carcinoma, soluble checkpoint and cytokine profiling, and prognostic marker validation against IMDC or MSKCC risk groups. Donors can be stratified by subtype, stage, risk group and treatment, with matched healthy controls available.
About Kidney Cancer Serum
Kidney Cancer Serum for Renal Cell Carcinoma and Tumour Immunology Research
Our Kidney Cancer Serum is sourced from IRB-consented donors clinically diagnosed with kidney cancer. Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality for oncology biomarker and tumour immunology studies. Kidney cancer is a neoplastic disease; the great majority of adult cases are renal cell carcinoma, most commonly the clear cell subtype.
Why Serum for Kidney Cancer Research
- Clear cell renal cell carcinoma is characterised by loss of VHL function, which stabilises hypoxia-inducible factors and drives constitutive transcription of VEGF and other angiogenic and glycolytic programmes. Serum is the practical matrix for measuring circulating VEGF and related angiogenic mediators that reflect that biology.
- Because the tumour is VEGF-driven, VEGF-directed tyrosine kinase inhibitors and HIF-2alpha inhibition are central to systemic therapy, and disease-state serum supports research into circulating correlates of angiogenesis-targeted treatment response.
- Renal cell carcinoma is also one of the more immune-infiltrated solid tumours and responds to immune checkpoint blockade, so serum supports profiling of soluble checkpoint molecules, chemokines and inflammatory cytokines that reflect tumour immune contexture.
- There is no validated screening tumour marker for renal cell carcinoma, which is precisely why disease-state serum matters: discovery and validation work in this indication depends on well-annotated patient material rather than an existing reference assay.
- Established prognostic risk models for advanced disease draw on routine blood parameters including corrected calcium, LDH, haemoglobin, neutrophils and platelets, so serum from risk-stratified donors lets researchers anchor novel markers against accepted clinical risk groups.
- Serum is the matrix on which most commercial oncology immunoassays are validated; matched kidney cancer plasma from the same donors is available where cell-free DNA or coagulation-sensitive analytes are the target.
Donor Stratification Available
- Histological subtype where documented: clear cell, papillary, or chromophobe renal cell carcinoma
- Stage and nuclear grade, and localised versus locally advanced or metastatic disease
- Prognostic risk group where documented, using IMDC or MSKCC criteria for advanced disease
- Treatment status: treatment-naive, post-nephrectomy, VEGF-targeted tyrosine kinase inhibitor, immune checkpoint inhibitor, or combination therapy
- Renal function and comorbidity context, including hypertension, chronic kidney disease and smoking history
- Matched healthy controls available, and non-malignant renal disease donors for comparison on request
Product Features
- Collected from clinically confirmed kidney cancer donors
- Research Use Only (RUO)
- Processed and frozen within 24 hours of collection
- IRB-approved protocols with documented consent
- Standard and custom aliquot volumes; volumes reported per lot
- Matched plasma, whole blood and PBMC from the same donors available on request
De-identified Donor Data
- Diagnosis confirmation
- Age, sex assigned at birth, and ethnicity
- Donor-reported medical history and comorbidities
- Subtype, stage and treatment details available on request
Applications
- Angiogenesis biomarker research, including VEGF and related circulating mediators
- Serum cytokine, chemokine and soluble immune checkpoint profiling
- Biomarker discovery and validation for prognosis and treatment response
- Tumour immunology research in an immune-infiltrated solid tumour
- Serum proteomics, glycoproteomics and metabolomics
- Tyrosine kinase inhibitor and checkpoint inhibitor response biomarker studies
- Therapeutic candidate screening and target validation
- Disease-state control matrix for oncology immunoassay qualification
Other Kidney Cancer Specimen Types
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Kidney cancer serum is available in standard and custom volumes. For pricing, current availability, or a quote on a stratified donor cohort, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse other disease states in this specimen type, visit our human serum page.
Applications
- Immunology and translational research
- Biomarker discovery and validation
- Drug screening and assay development
- Vaccine and infectious disease research
Product Features
- Research Use Only (RUO), Serum
- Sourced from screened, consented donors
- Processed under validated SOPs
- QC tested for purity, viability, and sterility
- Processed within 24 hours of collection
- IRB-approved protocols with electronic informed consent
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human Serum are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Pair with a Healthy Control
Match your Kidney Cancer Serum with normal donor samples for comparison
Healthy Serum
View InventoryNeed a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.